Publications by authors named "R C Driscoll"

Antibiotics have been well documented to result in several dermatological adverse reactions. Many of these adverse reactions are rashes that are difficult to distinguish. We present a case of a female patient in her 30s with acute generalised exanthematous pustulosis following vancomycin treatment for left breast cellulitis.

View Article and Find Full Text PDF

Background: Efforts to minimise inequity in palliative and end-of-life care (PEoLC) are well-researched. This is frequently explained by differences related to singular factors. The concept of intersectionality recognises that the combination of variables exacerbates disparities.

View Article and Find Full Text PDF

Sump syndrome is a rare complication of biliary surgery that is now rarely seen in the era of Endoscopic Retrograde Cholangiopancreatography (ERCP). It occurs when the distal common bile duct becomes obstructed between an anastomosis from a choledochoduodenostomy (CDD) and the ampulla of Vater, forming a sump that accumulates debris. Sump syndrome should be considered as a diagnosis in patients who present with cholangitis or pancreatitis and any history of biliary diversion, regardless of the time of presentation.

View Article and Find Full Text PDF

Sex-biased demography, including sex-biased survival or migration, can alter allele frequency changes across the genome. In particular, we can expect different patterns of genetic variation on autosomes and sex chromosomes due to sex-specific differences in life histories, as well as differences in effective population size, transmission modes, and the strength and mode of selection. Here, we demonstrate the role that sex differences in life history played in shaping short-term evolutionary dynamics across the genome.

View Article and Find Full Text PDF
Article Synopsis
  • There is a significant need for new treatments for glioblastoma (GBM), and acetazolamide has shown promise in enhancing the effectiveness of the existing treatment, temozolomide (TMZ), by addressing resistance mechanisms.
  • This phase I trial involved 24 patients with high-grade gliomas, administering acetazolamide alongside TMZ, and observed no dose-limiting toxicities while monitoring common side effects.
  • Results indicated a median overall survival of about 30 months for GBM patients, with a notable survival rate that suggests acetazolamide could be beneficial, warranting further investigation in randomized trials and highlighting BCL-3 expression as a potential prognostic marker.
View Article and Find Full Text PDF